Auris Medical Q3 2014 Earnings Release ZUG, Switzerland,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auris Medical Q3 2014 Earnings Release

ZUG, Switzerland, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (Nasdaq: EARS ) today provided an update on the Company's business and announced financial results for the third quarter ended September 30, 2014.

"We made great progress on clinical and operational fronts in the third quarter," commented Thomas Meyer, the Company's founder, Chairman and CEO. "We transitioned from a privately held to a publicly traded company, secured the funding to complete our important AM-101 development program in tinnitus, advanced our development projects and significantly raised our visibility among investors and inner ear specialists."

Recent Business Highlights

  • Completion of the initial public offering (IPO) in August 2014 raising net proceeds (after underwriting discounts) of $56.4 million. At the close of the third quarter 2014 (September 30, 2014), Auris Medical's cash and cash equivalents stood at CHF 61.9 million.
  • The AM-101 Phase 3 clinical program in acute inner ear tinnitus remains on track. Ramp-up of clinical trial sites in North America and Europe is expected to be completed in the first quarter of 2015. Enrolment into the post-acute arm ("Stratum B"; tinnitus onset between 3 and 12 months) of the TACTT3 trial continued to progress, with the goal of an interim analysis for futility testing in the first quarter of 2015, as previously announced.
  • In September 2014, Auris Medical organized a satellite symposium "Rational Pharmacotherapy for Tinnitus - Recent Advances and Perspectives" at the Annual Meeting of the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) in Orlando FL. The symposium featured talks from leading experts on scientific research, clinical endpoints, intratympanic drug delivery and clinical research in the field of tinnitus. The event was well attended and well received, and further raised awareness about our projects and therapeutic approaches within the otolaryngology community.
  • In September 2014, Auris Medical completed a Pre-IND meeting with the FDA on the AM-111 development program. The FDA provided formal feedback and guidance on the Company's pre-clinical and CMC development and specifically on the planned AM-111 late stage clinical program in acute sensorineural hearing loss (ASHNL). The Agency's feedback was sought in addition to protocol assistance obtained earlier from the European Medicines Agency. Based on the FDA's guidance and a general review of the development program by the Board of Directors, the Company is currently finalizing the design of the late-stage AM-111 clinical program. In parallel, Auris Medical is evaluating various non-dilutive financing options to secure comprehensive funding for the program.
  • During the third quarter, Auris Medical continued to strengthen and expand its intellectual property position. In Europe, the Company was granted European Patent 1928405 "Pharmaceutical compositions for the treatment of inner ear disorders" and filed a divisional application.

Financial Results

As of September 30, 2014, the Company had CHF 61.9 million in cash and cash equivalents. Operating expenses for the three months ended September 30, 2014 were CHF 5.6 million, with CHF 4.7 million attributable to research and development. This compares to operating expenses of CHF 4.2 million and research and development expenses of CHF 3.9 million for the same period in 2013. The Company reported a net loss for the quarter ended September 30, 2014 of CHF 3.4 million, or CHF 0.14 per share. This compares to a net loss of CHF 4.4 million, or CHF 0.27 per share, for the same period in 2013.

For the nine month period ended September 30, 2014, operating expenses were CHF 16.6 million, with CHF 13.0 million attributable to research and development. This compares to operating expenses of CHF 11.3 million and research and development expenses of CHF 10.3 million for the same period in 2013. The Company reported a net loss for the nine months ended September 30, 2014 of CHF 14.2 million, or CHF 0.69 per share. This compares to a net loss of CHF 11.5 million, or CHF 0.79 per share, for the same period in 2013.

The increases in operating expenses, and resulting increases in net loss, for the three- and nine-month periods ended September 30, 2014 over the comparable periods in 2013 reflect primarily the progression of the AM-101 Phase 3 clinical development program, preparations for the late stage AM-111 clinical program, headcount expansion and higher legal and auditing expenses related to the IPO preparations.

The Company expects the operating loss for the entire 2014 financial year to be in the range of CHF 22.5 to 24.5 million. This outlook is based on management's current expectations and beliefs.

Conference Call / Webcast Information

Auris Medical will host a live conference call and webcast to discuss the Company's financial results and provide a general business update. The call is scheduled for December 3, 2014 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time). To participate in this conference call, dial 1877 280 2296 (USA) or +1 646 254 3364 (International), and enter passcode 9517081. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at: www.aurismedical.com . A replay will be available approximately two hours following the live call also on the Company's website.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's prospectus relating to its Registration Statement on Form F-1, as amended, and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Auris Medical Holding AG
Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income
(unaudited)
(in CHF thousands, except per share data)
         
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
Research and development expenses (4,686) (3,943) (13,036) (10,327)
General and administrative expenses (998) (278) (3,522) (1,010)
Operating loss (5,684) (4,221) (16,588) (11,337)
Finance income / expense (net) 2,323 (208) 2,376 (168)
Loss before tax (3,361) (4,429) (14,212) (11,506)
Net loss attributable to owners of the Company (3,361) (4,429) (14,212) (11,506)
Other comprehensive income:        
Items that will never be reclassified to profit or loss        
Remeasurements of defined benefits liability 112 3 (312) 95
Items that are or may reclassified to profit or loss        
Foreign currency translation differences (74) 39 (71) 13
Other comprehensive income 37 43 (384) 109
Total comprehensive loss attributable to owners of the Company (3,323) (4,386) (14,596) (11,397)
Loss per share, basic and diluted (0.14) (0.27) (0.69) (0.79)
Weighted average common shares outstanding, basic and diluted  24,589,852 16,217,825 20,488,392 14,496,230
Currency rate CHF / USD 0.9134 0.9326 0.8960 0.9330
 
Auris Medical Holding AG
Condensed Consolidated Interim Statement of Financial Position (unaudited)
(in CHF thousands)
     
  September 30,
2014
December 31,
2013
Assets    
Non-current assets    
Property and equipment 245 196
Intangible assets 1,483 1,483
Total non-current assets 1,728 1,678
Current assets    
Current financial assets and other receivables 712 525
Prepayments 333 183
Cash and cash equivalents 61,893 23,866
Total current assets 62,938 24,574
Total assets 64,666 26,252
Equity and Liabilities    
Equity    
Share capital 11,582 6,487
Share premium 93,793 35,608
Foreign currency translation reserve (17) 54
Accumulated deficit (47,402) (33,116)
Total shareholders' equity attributable to owners of the Company 57,956 9,034
Non-current liabilities    
Employee benefits 627 328
Deferred tax liabilities 328 328
Total non-current liabilities 955 656
Current liabilities    
Convertible loans -- 13,711
Trade and other payables 3,613 954
Accrued expenses 2,142 1,897
Total current liabilities 5,755 16,562
Total liabilities 6,710 17,219
Total equity and liabilities 64,666 26,252
Currency rate CHF / USD 0.9574 0.8894

Contact:
Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, ear@aurismedical.com

Auris Medical Q3 2014 Earnings Release: http://hugin.info/160190/R/1876494/661404.pdf

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 42

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 68

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 80

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 160

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Investors in Metagenomi Class Action

Updated Category News Views 103

Key Deadline for Metagenomi Investors As investors in Metagenomi, Inc. keep a close watch, an important deadline is approaching. The time to file a lead plaintiff motion in the class action lawsuit is set for November 25, 2024. This action is vital for those who purchased or acquired Metagenomi securities, specifically those linked to the company’s latest initial public...

Continue Reading
Structure Therapeutics Engages with Investors at Key Conferences

Updated Category News Views 78

Structure Therapeutics Engages with Investors at Key Conferences Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company, is gearing up to participate in important investor conferences this September. The company is dedicated to developing innovative oral small molecule therapeutics aimed at treating metabolic and cardiopulmonary...

Continue Reading
OmaSp Reports Solid Financial Performance with Growth Prospects

Updated Category News Views 156

OmaSp's Strong Financial Performance and Future Outlook OMA SAVINGS BANK PLC has recently released its financial statements for the year ending December 31, 2024, showing promising results and projections for continued growth. Known as OmaSp, the bank reported a noteworthy fourth quarter, aligning with the expectations set forth at the beginning of the year, and a solid...

Continue Reading
Unveiling the Reagan National Economic Forum for Future Growth

Updated Category News Views 485

Reagan National Economic Forum Set to Inspire Economic Solutions The Ronald Reagan Presidential Foundation and Institute is gearing up for a transformative inaugural economic summit with leading figures from the business and economic policy landscapes to take place in late May 2025. About the Forum’s Objectives The Reagan National Economic Forum (RNEF) aims to provide a...

Continue Reading
Experience the Vibrant Latin Business Networking Event of 2025

Updated Category News Views 279

Celebrating the Latino Business Community Prepare yourself for an unforgettable networking event dedicated to the Latino business community, brought to you by Latin Biz Today and Mercy University. The Spectrum of Success event promises a night filled with excitement, learning, and cultural experiences that will leave a lasting impression on everyone involved. A Night of...

Continue Reading